Ask about this productRelated genes to: NR4A2 antibody
- Gene:
- NR4A2 NIH gene
- Name:
- nuclear receptor subfamily 4 group A member 2
- Previous symbol:
- NURR1
- Synonyms:
- TINUR, NOT, RNR1, HZF-3
- Chromosome:
- 2q22-q23
- Locus Type:
- gene with protein product
- Date approved:
- 1997-07-11
- Date modifiied:
- 2015-11-18
Related products to: NR4A2 antibody
Related articles to: NR4A2 antibody
- Gallbladder cancer (GBC) originating from the fundus/body (GBC) and neck/cystic duct (GBC) exhibits distinct clinical outcomes. Location-associated heterogeneity is intricately linked to oncogenic properties and multicellular interactions within the tumor microenvironment (TME). - Source: PubMed
Publication date: 2026/04/17
Shi XuebingLi ShuaiBai MixueXie ZhihuaCheng QingbaoQiu XinyaoZhou TaoJiang XinyuYang ShuaiHu JiXue DongdongLiu ShuowuZhang YaniWang YixianWu JingBao JinxiaWang HongyangJiang XiaoqingChen Lei - - Source: PubMed
Publication date: 2026/04/16
Stujanna Endin NokikYoshioka Jun - Effector CD8 T cells are key cellular drivers of type 1 diabetes (T1D) pathogenesis, yet questions remain regarding the molecular defects leading to altered cytotoxicity, their signature in peripheral tissues, and their receptor specificity. Thus, we analyzed human pancreatic lymph nodes (pLN) using mass cytometry and single cell RNA sequencing (scRNAseq) with combined proteomic and T cell receptor (TCR) profiling. Cytometric analysis revealed an enriched population of T stem-cell memory (TSCM)-like cells (CD8CD45RACD27CD28CCR7CXCR3 T cells) in T1D pLNs. scRNAseq profiling indicated an elevated inflammatory cytokine gene signature (, ) along with regulators of terminal differentiation (, ), coupled with reduced expression of exhaustion-associated genes (, , ) in CD8 T cells in T1D pLN. Additionally, effector CD8 T cells expressed features of progenitor exhausted cells () in T1D pLN. Immune Response Enrichment Analysis (IREA) indicated IL-15 signaling as a significant driver of these phenotypes. Integrated TCR and transcriptomic analysis revealed a cluster of diverse naïve-like CD8 T cell clones in T1D pLN. When comparing pLN and pancreatic slice cellular isolates, we observed sharing of effector CD8 T cells, with upregulation of terminal effector signatures detected within the pancreas relative to paired pLN samples. Multiplex imaging revealed differential localization of TCF1 and TOX expressing T cells in the pancreas, with TCF1TOX cells located in closer proximity to the islets and displaying a mixture of activation and exhaustion-associated phenotypes. Thus, we provide multimodal cellular profiles enriched in T1D tissues for consideration in therapeutic targeting. - Source: PubMed
Publication date: 2026/04/01
Peters Leeana DSeay Howard RSmith JustinPosgai Amanda LBerkowitz ReedWasserfall Clive HAtkinson Mark ABacher RhondaBrusko Maigan ABrusko Todd M - Cytokine armoring of CAR T cells for enhancing the immunotherapy of cancer. Reprogramming of CAR T-cell phenotypes through (a) IL-15 or (b) IL-9Rα engineering. Reprogramming of the tumor microenvironment and recruitment of host antitumor immunity through (c) IL-36γ or (d) IL-12 engineering. (e) Tumor-inducible cytokine expression utilizing synthetic NFAT or endogenous NR4A2 promoter systems to restrict systemic expression of potent cytokines for improved safety. - Source: PubMed
Publication date: 2026/04/05
Sek KevinYap Kah MinHong Woon XuanDarcy Phillip K - Parkinson's disease (PD) is a progressive neurodegenerative disorder marked by degeneration of dopaminergic neurons and associated motor impairments. Current pharmacotherapies only offer symptomatic relief hampered by multiple adverse effects. Herein, pharmacologic, molecular and histopathologic studies were employed to determine whether valsartan (VAL) has functional neurorestorative potential in PD male rat model induced by intraperitoneal (IP) injection of haloperidol (HALO) (1.5 mg/kg/day, for 42 days). Administration of VAL (40 mg/kg PO) for 21 days markedly improved motor functions as revealed by i) reduced muscle rigidity in catalepsy bar test, ii) increase in performance in rotarod and beam walking tests, iii) increased total distance travelled, grooming duration, rearing duration, and maximum speed in open field test. Western blot analysis revealed that VAL restored the markers of dopaminergic neuronal degeneration as indicated by increased protein expression of dopaminergic-specific transcription factors (Nurr1, ASCL1) and mRNA expression of Nurr1 regulatory proteins (PIN1, CoREST), the dopamine (DA) neurons detoxifier ALDH1A1, and markers for dopaminergic transmission (D2 receptor, tyrosine hydroxylase (TH), DA transporter (DAT). Histopathological analyses confirmed neuronal integrity in the substantia nigra (SN). Furthermore, VAL exerted epigenetic modulation by downregulating histone deacetylases HDAC1/5 and upregulating sirtuin 1 (SIRT1), decreased α-synuclein (α-syn) and restored ApoA1. Co-administration of Nurr1 inhibitor meloxicam (MLX; 3 mg/Kg/day PO) significantly attenuated VAL's neuroprotective effects, confirming Nurr1's central role, but did not fully reverse its epigenetic actions. In conclusion, VAL demonstrated potent neuroprotective, restorative of neuronal function, and epigenetic modulatory effects in PD, highlighting its promising role as a novel disease-modifying therapeutic candidate and warranting further investigation. - Source: PubMed
Publication date: 2026/04/03
Gowied Hadeer GEl-Mezayen Nesrine SAfify Elham A